SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Prepaid Assets came in at $3.8 million in Q1 2026, up 11.98% YoY from $3.4 million in Q1 2025, and up 9.17% on a QoQ basis from $3.5 million in Q4 2025.
SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Prepaid Assets data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Prepaid Assets rose 11.98% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 11.98% YoY) and the FY2025 annual result came in at $3.5 million, up 18.03% from the prior year.
- Prepaid Assets improved to $3.8 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $3.8 million in Q1 2026 to a low of $702231.0 in Q3 2023.
- A 5-year average of $2.2 million and a median of $2.0 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 1038.56% — and 2023, when it slumped 59.57%.
- Tracing SABS's Prepaid Assets over 5 years: stood at $1.5 million in 2022, then surged by 56.68% to $2.3 million in 2023, then advanced by 27.16% to $3.0 million in 2024, then increased by 18.03% to $3.5 million in 2025, then gained by 9.17% to $3.8 million in 2026.
- The last three Prepaid Assets figures came in at $3.8 million (Q1 2026), $3.5 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.46 Mn |
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 2.98 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 702,231.00 |
| Jun 30, 2023 | 867,604.00 |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 907,865.00 |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 2.99 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 102,742.00 |